Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.32 USD | -0.37% | +19.55% | -11.19% |
Business Summary
Number of employees: 536
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Oral Small Molecule and Protein Therapeutics
100.0
%
| 271 | 100.0 % | 331 | 100.0 % | +22.37% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
87.0
%
| - | - | 288 | 87.0 % | - |
Non-United States
11.4
%
| - | - | 38 | 11.4 % | - |
Global
1.6
%
| 271 | 100.0 % | 5 | 1.6 % | -98.00% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Jon Stonehouse
CEO | Chief Executive Officer | 63 | 06-12-31 |
Anthony Doyle
DFI | Director of Finance/CFO | 44 | 20-04-01 |
Ryan Arnold
CTO | Chief Tech/Sci/R&D Officer | - | 22-02-28 |
Helen Thackray
CTO | Chief Tech/Sci/R&D Officer | 55 | 19-09-19 |
Philip George
PRN | Corporate Officer/Principal | - | 22-08-31 |
Corporate Officer/Principal | - | 14-12-31 | |
Charles Gayer
PRN | Corporate Officer/Principal | 53 | 15-07-31 |
Human Resources Officer | - | 18-10-31 | |
Salisa Hauptmann
LAW | General Counsel | - | 20-12-31 |
Corporate Officer/Principal | 61 | 22-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Alan Levin
BRD | Director/Board Member | 62 | 20-02-26 |
Jon Stonehouse
CEO | Chief Executive Officer | 63 | 06-12-31 |
Director/Board Member | 60 | 21-07-25 | |
Stephen Aselage
BRD | Director/Board Member | 73 | 19-01-03 |
Director/Board Member | 69 | 11-10-09 | |
Nancy Hutson
CHM | Chairman | 74 | 12-01-19 |
Helen Thackray
CTO | Chief Tech/Sci/R&D Officer | 55 | 19-09-19 |
Steven Galson
BRD | Director/Board Member | 67 | 21-08-31 |
Theresa Heggie
BRD | Director/Board Member | 63 | 18-12-02 |
Amy McKee
BRD | Director/Board Member | 52 | 21-09-19 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 206,377,088 | 200,378,726 ( 97.09 %) | 0 | 97.09 % |
Company contact information
BioCryst Pharmaceuticals, Inc.
4505 Emperor Boulevard Suite 200
27703-8457, Durham
+919 859 1302
http://www.biocryst.comSector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.19% | 1.1B | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- BCRX Stock
- Company BioCryst Pharmaceuticals, Inc.